[Form 3] Electra Therapeutics, Inc. Initial Statement of Beneficial Ownership

Electra Therapeutics, Inc. (symbol: ETRA) is the issuer of record for a Form 3 filing submitted to the SEC.

Rhea-AI Filing Summary

Electra Therapeutics, Inc. (symbol: ETRA) is the issuer of record for a Form 3 filing submitted to the SEC.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Stagliano Nancy

Role Director

Type	Security	Shares	Price	Value
holding	Director Stock Option (right to buy) F1, F2	--	--	--
holding	Director Stock Option(right to buy) F3	--	--	--
holding	Director Stock Option (right to buy) F4	--	--	--
holding	Series A Convertible Preferred Stock F5	--	--	--

Holdings After Transaction: Director Stock Option (right to buy) — 94,538 contracts (Indirect, By The Nancy E. Stagliano Trust); Director Stock Option(right to buy) — 288,814 contracts (Direct); Director Stock Option (right to buy) — 68,819 contracts (Direct); Series A Convertible Preferred Stock — 255,635 contracts (Direct)

Footnotes (5)

1. F1. The shares subject to this option are fully vested.
2. F2. The Reporting Person is trustee of the trust.
3. F3. 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
4. F4. The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.
5. F5. Each share of Series A Convertible Preferred Stock (the "Preferred Stock") will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 08:25 PM Accepted by SEC EDGAR 09/18/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stagliano Nancy

(Last) (First) (Middle)

C/O ELECTRA THERAPEUTICS, INC.

230 E GRAND AVENUE, SUITE S-100

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2026

3. Issuer Name and Ticker or Trading Symbol
Electra Therapeutics, Inc. [ ETRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	(1)	03/23/2032	Common Stock	94,538	$5.23	I	By The Nancy E. Stagliano Trust(2)
Director Stock Option(right to buy)	(3)	02/12/2036	Common Stock	288,814	$4.96	D
Director Stock Option (right to buy)	(4)	09/16/2036	Common Stock	68,819	$15	D
Series A Convertible Preferred Stock	(5)	(5)	Common Stock	255,635	(5)	D

Explanation of Responses:

1. The shares subject to this option are fully vested.

2. The Reporting Person is trustee of the trust.

3. 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

4. The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.

5. Each share of Series A Convertible Preferred Stock (the "Preferred Stock") will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.

	/s/ Jamie Kitano, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)